AstraZeneca's Atacand Heart Failure Indication Clears FDA Ahead Of Cmte. Review

The agency approves candesartan for treatment of heart failure to reduce cardiovascular mortality and hospitalizations. The angiotensin receptor blocker is the first product in its class to receive the claim. Approval comes two days before an FDA advisory panel review.